Press Releases Filter By Year 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 May 2, 2019 Valneva Reports Strong Q1 2019 Operating Results and Advances Key R&D Programs towards Major Milestones April 9, 2019 Valneva to Present on Lyme and Chikungunya Vaccine Candidates at the 19th World Vaccine Congress April 3, 2019 Valneva Announces Termination of 2013 Shareholder Agreement March 25, 2019 Valneva Announces the Publication of its 2018 Registration Document March 21, 2019 Valneva Announces the Availability of its FY 2018 Audited Consolidated and Statutory Financial Statements February 21, 2019 Valneva Reports Strong 2018 Results, Expects Further Growth and Major Pipeline Progression in 2019 January 31, 2019 Valneva Reports Positive Initial Booster Data and Final Phase 1 Data for its Lyme Disease Vaccine Candidate January 16, 2019 Valneva Confirms FY 2018 Guidance and Provides Initial Product Sales Revenue Guidance for 2019 January 16, 2019 Valneva Announces New $59 Million IXIARO® Supply Contract with US Government January 7, 2019 Valneva Announces its Intention to Delist from the Vienna Stock Exchange 1 2 3 4 … 27
May 2, 2019 Valneva Reports Strong Q1 2019 Operating Results and Advances Key R&D Programs towards Major Milestones
April 9, 2019 Valneva to Present on Lyme and Chikungunya Vaccine Candidates at the 19th World Vaccine Congress
March 21, 2019 Valneva Announces the Availability of its FY 2018 Audited Consolidated and Statutory Financial Statements
February 21, 2019 Valneva Reports Strong 2018 Results, Expects Further Growth and Major Pipeline Progression in 2019
January 31, 2019 Valneva Reports Positive Initial Booster Data and Final Phase 1 Data for its Lyme Disease Vaccine Candidate
January 16, 2019 Valneva Confirms FY 2018 Guidance and Provides Initial Product Sales Revenue Guidance for 2019
